JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265075

Human FCGRT (FCRN) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

FCGRT KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 14 bp deletion in exon 3.

View Alternative Names

FCGRN_HUMAN, FCGRT, Fc fragment of IgG, receptor transporter, alpha, FcRn, FcRn alpha chain, IgG Fc fragment receptor transporter alpha chain, IgG Gc receptor, IgG receptor FcRn large subunit p51, IgG receptor FcRn large subunit p51 precursor, Immunoglobulin receptor, intestinal, heavy chain, Neonatal Fc receptor

2 Images
Western blot - Human FCGRT (FCRN) knockout HEK-293T cell line (AB265075)
  • WB

Lab

Western blot - Human FCGRT (FCRN) knockout HEK-293T cell line (AB265075)

Lanes 1-4 : Merged signal (red and green). Green - ab228975 observed at 40 kDa. Red - loading control ab8245 observed at 38 kDa.

ab228975 Anti-FCGRT/FCRN antibody [EPR22627-25] was shown to specifically react with FCGRT/FCRN in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line ab265075 (knockout cell lysate ab257435) was used. Wild-type and FCGRT/FCRN knockout samples were subjected to SDS-PAGE. ab228975 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-FCGRT/FCRN antibody [EPR22627-25] (<a href='/en-us/products/primary-antibodies/fcgrt-fcrn-antibody-epr22627-25-ab228975'>ab228975</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK-293T (non-ATCC) cell lysate at 20 µg

Lane 2:

Western blot - Human FCGRT (FCRN) knockout HEK-293T cell lysate (<a href='/en-us/products/cell-lysates/human-fcgrt-fcrn-knockout-hek-293t-cell-lysate-ab257435'>ab257435</a>)

Lane 2:

Human FCGRT (FCRN) knockout HEK-293T (non-ATCC) cell lysate (<a href='/en-us/products/cell-lysates/human-fcgrt-fcrn-knockout-hek-293t-cell-lysate-ab257435'>ab257435</a>)

Lane 3:

HEK293 (ATCC) cell lysate at 20 µg

Lane 4:

LNCaP cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 40 kDa

Observed band size: 40 kDa

false

Sanger Sequencing - Human FCGRT (FCRN) knockout HEK-293T cell line (AB265075)
  • Sanger seq

Unknown

Sanger Sequencing - Human FCGRT (FCRN) knockout HEK-293T cell line (AB265075)

Homozygous : 14 bp deletion in exon 3.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 14 bp deletion in exon 3

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265075-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265075 Human FCGRT (FCRN) knockout HEK-293T cell line", "number":"AB265075-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
FCGRT
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C
style
left-column

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein FCGRT also known as FCRN or FcRn has a significant role in the immune system by binding to the Fc region of immunoglobulin G (IgG). This binding prolongs the half-life of IgG by preventing its lysosomal degradation. The molecular mass of the FCGRT protein is roughly 52 kDa. It is prominently expressed in epithelial and endothelial cells across several tissues including the placenta and liver ensuring IgG stability in circulation.
Biological function summary

FCGRT/FCRN is involved in the transportation and recycling of IgG antibodies. It forms a complex with beta-2 microglobulin that contributes to its function. This complex allows IgG antibodies to traverse cellular barriers such as epithelial cells without being digested. This protein is important in maintaining humoral immunity by regulating IgG levels in the bloodstream and similar processes can be observed in mouse FCRN and cynomolgus monkey milk indicating a conserved mechanism across species.

Pathways

FCGRT/FCRN plays a part in the neonatal Fc receptor pathway. This pathway influences IgG homeostasis and impacts antigen presentation to T cells. By doing so it affects immune surveillance and immune tolerance mechanisms. The pathway involves interactions with related proteins such as albumin which also binds to FCRN for extending its half-life in serum.

Disruptions in FCGRT/FCRN functionality relate to autoimmune conditions and inflammatory diseases. Conditions such as lupus and myasthenia gravis show altered IgG recycling or transportation implicating FCRN in their pathology. Accordingly researchers have explored FCRN inhibitors as potential therapeutic interventions. These inhibitors aim to modulate the interaction between FCRN and IgG therefore impacting the disease progression linked to these disorders.
style
left-column
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column

Target data

See full target information FCGRT
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB228975

Anti-FCGRT/FCRN antibody [EPR22627-25]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FCGRT/FCRN antibody [EPR22627-25] (AB228975)

  • 0
  • 0
Cell Lines & Lysates

AB266116

Human ARRB2 (Beta Arrestin 2) knockout HEK-293T cell line

Advanced Validation

Western blot - Human ARRB2 (Beta Arrestin 2) knockout HEK-293T cell line (AB266116)

  • 0
  • 0
Cell Lines & Lysates

AB267334

Human CLTA (Clathrin light chain A) knockout HEK-293T cell line

Advanced Validation

Western blot - Human CLTA (Clathrin light chain A) knockout HEK-293T cell line (AB267334)

  • 0
  • 0
Cell Lines & Lysates

AB266324

Human CD47 knockout HEK-293T cell line

Advanced Validation

Immunocytochemistry/ Immunofluorescence - Human CD47 knockout HEK-293T cell line (AB266324)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com